We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+6.14%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$99.1B
AUM Growth
+$7.92B
Cap. Flow
+$3.27B
Cap. Flow %
3.3%
Top 10 Hldgs %
23.39%
Holding
4,186
New
432
Increased
2,037
Reduced
1,399
Closed
199

Sector Composition

Rank Sector Weight
1 Technology 14%
2 Financials 8.86%
3 Healthcare 8.09%
4 Industrials 6.83%
5 Consumer Discretionary 6.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SO icon
3926
CALL
Southern Company
SO
$106B
$6K ﹤0.01%
+22,000
New +$1.32M
WES icon
3927
PUT
Western Midstream Partners
WES
$19.9B
$6K ﹤0.01%
+17,000
New +$289K
JNJ icon
3928
CALL
Johnson & Johnson
JNJ
$626B
$5K ﹤0.01%
31,800
-4,600
-13% -$744K
GUT.RT
3929
DELISTED
Gabelli Utility Trust (The) Rights (expiring April 14, 2021)
GUT.RT
$5K ﹤0.01%
+44,121
New +$6.46K
CMP icon
3930
CALL
Compass Minerals
CMP
$1.13B
$4K ﹤0.01%
18,900
GLNG icon
3931
CALL
Golar LNG
GLNG
$5.17B
$4K ﹤0.01%
+37,100
New +$417K
TMUS icon
3932
CALL
T-Mobile US
TMUS
$192B
$4K ﹤0.01%
+16,700
New +$2.1M
BODI icon
3933
CALL
The Beachbody Company
BODI
$45.6M
$4K ﹤0.01%
+242
New +$136K
ABBV icon
3934
CALL
AbbVie
ABBV
$442B
$3K ﹤0.01%
10,200
-47,500
-82% -$5.08M
BCLI
3935
CALL
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$3K ﹤0.01%
+1,667
New +$126K
GILD icon
3936
CALL
Gilead Sciences
GILD
$168B
$3K ﹤0.01%
+12,500
New +$806K
NLY icon
3937
CALL
Annaly Capital Management
NLY
$17.4B
$3K ﹤0.01%
+3,750
New +$127K
QFIN icon
3938
CALL
Qfin Holdings
QFIN
$1.56B
$3K ﹤0.01%
+10,200
New +$227K
USB icon
3939
CALL
US Bancorp
USB
$100B
$3K ﹤0.01%
+15,000
New +$749K
FRO icon
3940
CALL
Frontline
FRO
$8.49B
$2K ﹤0.01%
+15,300
New +$105K
VICI icon
3941
CALL
VICI Properties
VICI
$28.6B
$2K ﹤0.01%
+16,500
New +$448K
QNTM
3942
CALL
Quantum Biopharma Class B Subordinate Voting Shares
QNTM
$22.8M
$2K ﹤0.01%
+231
New +$32.3K
ADMA icon
3943
CALL
ADMA Biologics
ADMA
$2.22B
$1K ﹤0.01%
15,000
-3,000
-17% -$6.87K
BP icon
3944
CALL
BP
BP
$111B
$1K ﹤0.01%
+18,900
New +$455K
F icon
3945
CALL
Ford
F
$55.7B
$1K ﹤0.01%
10,500
-4,000
-28% -$45.8K
LUMN icon
3946
CALL
Lumen
LUMN
$6.58B
$1K ﹤0.01%
+19,400
New +$241K
VTRS icon
3947
CALL
Viatris
VTRS
$18.7B
$1K ﹤0.01%
+30,300
New +$494K
XOM icon
3948
CALL
ExxonMobil
XOM
$657B
$1K ﹤0.01%
+11,700
New +$613K
ACAD icon
3949
Acadia Pharmaceuticals
ACAD
$5.07B
-31,372
Closed -$1.68M
ACCO icon
3950
Acco Brands
ACCO
$396M
-39,229
Closed -$331K

Similar funds

Raymond James & Associates's Q1 2021 Portfolio in Review

As of Q1 2021, Raymond James & Associates held 4,186 positions worth $99.1B, up 8.7% from $91.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Raymond James & Associates deployed $3.27B of net new capital in Q1 2021, opening 432 new positions and adding to 2,037 existing holdings. Its largest new stake was BlackRock Technology and Private Equity Term Trust: 1,676,875 shares worth $34M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Vanguard High Dividend Yield ETF, an estimated $671M trimmed.

  • Raymond James & Associates's largest Q1 2021 buy was BlackRock Technology and Private Equity Term Trust: 1,676,875 shares worth $34M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q1 2021, an estimated $1.36B increase.
  • Raymond James & Associates's biggest Q1 2021 reduction was Vanguard High Dividend Yield ETF, cutting an estimated $671M.
  • Raymond James & Associates fully exited Sensient Technologies in Q1 2021, selling an estimated $15.6M.
  • Raymond James & Associates's ten largest holdings make up 23% of its $99.1B portfolio in Q1 2021.
  • Raymond James & Associates opened 432 new positions and closed 199 in Q1 2021.
  • Raymond James & Associates's portfolio value rose 8.7% quarter-over-quarter to $99.1B.

Based on Raymond James & Associates's 13F filing for Q1 2021, filed 14 May 2021.